Marker Therapeutics is trading at $0.99, down 7.01%; sector pressure offers context, but the cause of the larger decline remains uncertain. - No company-specific catalyst was identified for October 23. The latest reported company news was an October 19 FDA grant announcement, which does not explain the decline. - Biotechnology shares were also weaker, with XBI reported down 1.68% during the session.